SAN DIEGO, Sept. 14, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the appointment of David P. Meininger, PhD, MBA, to the newly created position of Senior Vice President of Business Development, effective today. In this role, Dr. Meininger will be responsible for developing new business and strategic partnerships as well as potential licensing opportunities. He will also manage all corporate development activities for the Company's therapeutic products.
"I'm thrilled to welcome David to the OncoSec team. David brings more than 20 years of experience in basic and applied scientific research, and has led growth-oriented teams at prominent biotech and pharmaceutical companies, including Merck. He also brings complimentary experience to OncoSec's business development focus in the field of immuno-oncology," said Punit Dhillon, CEO and President of OncoSec. "His extensive business experience and industry-acumen will provide immense value to OncoSec as we continue to expand our drug discovery and development activities."
Most recently, Dr. Meininger served as Executive Director, Business Development and Licensing at Merck & Co., Inc., where he was the global lead for biologics technologies and was responsible for West Coast in-licensing opportunities in immuno-oncology and other therapy areas. Prior to his Business Development role at Merck, Dr. Meininger served as Executive Director, Molecular Discovery. In this position, he led a team focused on discovery, initial production, characterization, and validation of large-molecule leads for programs across seven Disease Area Franchises in addition to championing multiple biologics discovery initiatives, including several supporting KEYTRUDA® (pembrolizumab).
Prior to joining Merck, Dr. Meininger was Vice President, Biotherapeutics at Boehringer Ingelheim GmbH. While at Boehringer Ingelheim GmbH, he led the New Biological Entity Discovery Unit focusing on the discovery, design, and early development of New Biological Entities. He was also Principal Scientist, Department of Protein Science at Amgen Inc. where his team supported multiple Amgen Oncology and Inflammation Therapeutic Area projects.
Dr. Meininger earned a bachelor's degree in chemistry from the University of Florida and a PhD in biochemistry from the University of California, San Diego. He also earned a MBA in technology management from the University of Washington.
About OncoSec Medical Incorporated
OncoSec is a biopharmaceutical company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck (HNSCC), and triple-negative breast cancer (TNBC). In addition to ImmunoPulse™ IL-12, the company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
CONTACT: Investor Relations: Jordyn Kopin OncoSec Medical Incorporated 855-662-6732 firstname.lastname@example.org
Media Relations: Mary Marolla OncoSec Medical Incorporated 855-662-6732 email@example.com
SOURCE OncoSec Medical Incorporated